Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.11)
# 1,104
Out of 4,842 analysts
101
Total ratings
44.83%
Success rate
1.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Assumes: Overweight | $13 | $4.31 | +201.62% | 1 | May 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $58.09 | +54.93% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $445.10 | +7.84% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $46.97 | +17.10% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $108.44 | -26.23% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $3.14 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $591.85 | +71.50% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $278.40 | +45.47% | 2 | Oct 22, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $285.81 | -23.03% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $7.98 | +25.31% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $4.07 | +59.71% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $37.23 | +93.42% | 1 | Apr 13, 2023 |
Vanda Pharmaceuticals
May 14, 2025
Assumes: Overweight
Price Target: $13
Current: $4.31
Upside: +201.62%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $58.09
Upside: +54.93%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $445.10
Upside: +7.84%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $46.97
Upside: +17.10%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $108.44
Upside: -26.23%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.14
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $591.85
Upside: +71.50%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $278.40
Upside: +45.47%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $285.81
Upside: -23.03%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.98
Upside: +25.31%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $4.07
Upside: +59.71%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $37.23
Upside: +93.42%